| Medical and Health Sciences | 2021-2025 | 137 | KR 3 | 99.97 |
| Pulmonary and Respiratory Medicine | Lifetime | 64 | KR 1 | 99.92 |
| Oncology | Lifetime | 129 | KR 3 | 99.79 |
| Cancer Research | Lifetime | 974 | KR 5 | 92.49 |
| Otolaryngology | Lifetime | 517 | KR 9 | 87.47 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 12 | KR 2 | 99.94 |
| Oncology | 2021-2025 | 24 | KR 2 | 99.87 |
| Surgery | 2021-2025 | 738 | KR 14 | 93.54 |
| Cancer Research | 2021-2025 | 165 | KR 3 | 91.36 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 537 | KR 16 | 88.77 |
| Lung Cancer Treatments and Mutations | Lifetime | 29 | KR 1 | 99.91 |
| Lung Cancer Research Studies | Lifetime | 24 | KR 1 | 99.85 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 87 | KR 2 | 99.76 |
| Colorectal Cancer Treatments and Studies | Lifetime | 53 | KR 2 | 99.73 |
| Lung Cancer Diagnosis and Treatment | Lifetime | 71 | KR 3 | 99.72 |
| Cancer therapeutics and mechanisms | Lifetime | 83 | KR 2 | 99.37 |
| Cancer Genomics and Diagnostics | Lifetime | 237 | KR 3 | 99.50 |
| Peptidase Inhibition and Analysis | Lifetime | 383 | KR 4 | 98.53 |
| Brain Metastases and Treatment | Lifetime | 167 | KR 1 | 98.67 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 312 | KR 30 | 98.61 |
| Gastric Cancer Management and Outcomes | Lifetime | 680 | KR 47 | 98.62 |
| Neuroendocrine Tumor Research Advances | Lifetime | 419 | KR 5 | 98.49 |
| Radiomics and Machine Learning in Medical Imaging | Lifetime | 789 | KR 50 | 97.91 |
| HER2/EGFR in Cancer Research | Lifetime | 455 | KR 12 | 98.06 |
| Head and Neck Cancer Studies | Lifetime | 569 | KR 9 | 97.89 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 470 | KR 6 | 96.54 |
| Advanced Breast Cancer Therapies | Lifetime | 939 | KR 19 | 92.78 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 12 | KR 2 | 99.93 |
| Lung Cancer Research Studies | 2021-2025 | 13 | KR 2 | 99.87 |
| Lung Cancer Diagnosis and Treatment | 2021-2025 | 39 | KR 3 | 99.42 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 29 | KR 2 | 99.58 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 185 | KR 4 | 99.30 |
| Cancer Genomics and Diagnostics | 2021-2025 | 170 | KR 3 | 98.71 |
| Cancer therapeutics and mechanisms | 2021-2025 | 24 | KR 2 | 97.88 |
| Peptidase Inhibition and Analysis | 2021-2025 | 76 | KR 4 | 98.13 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 154 | KR 2 | 96.21 |
| Salivary Gland Tumors Diagnosis and Treatment | 2021-2025 | 67 | KR 1 | 96.12 |
| Brain Metastases and Treatment | 2021-2025 | 142 | KR 3 | 95.25 |
| HER2/EGFR in Cancer Research | 2021-2025 | 181 | KR 10 | 97.20 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 579 | KR 36 | 95.85 |
| Head and Neck Cancer Studies | 2021-2025 | 567 | KR 10 | 92.64 |
| Melanoma and MAPK Pathways | 2021-2025 | 784 | KR 14 | 71.51 |
